Skip to main content

Drug Safety

Noninflammatory Pain Persists in RA Despite Treatment

Jun 02, 2020

Almost one-third of patients with new-onset rheumatoid arthritis (RA) reported persistent unacceptable pain after 21 months of combination therapy, according to a study by Swedish researchers.A total of 29% of patients continued to have unacceptable pain.

Read Article

First Look at COVID-19 Global Rheumatology Alliance Registry

Jun 01, 2020

Gianfresco et al have published the first peer-reviewed analysis of COVID-19 infected, rheumatic disease patients entered into the Rheumatology Global Alliance registry; showing that a) rheumatic disease patient can be infected with COVID-19, b) that DMARD and biologic use has no apparent effect

Read Article

RheumNow Podcast - Rheumatic Patients with COVID (5.29.20)

May 29, 2020

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
UPI quotes Dr. Tony Fauci stating (about hydroxychloroquine) "The scientific data is really quite evident now about the lack of efficacy". Yesterday France and other countries have banned the use of HCQ to treat COVID. https://t.co/G0EuWMGTdW

Dr. John Cush RheumNow ( View Tweet)

May 28, 2020

Targeting the Wnt Pathway Fails in OA

May 28, 2020

The Wnt pathway modulator lorecivivint failed to meet the primary endpoint in a phase IIa study for knee osteoarthritis (OA), but showed promise in certain patient subgroups, researchers reported.

Read Article
BTK inhib (fenbrutinib-FEN) effective in #RA. In a 12 wk RCT, 480 MTX-IR pts Rx either PBO, adalimumab or FEN (50 mg or 150 mg/d). ACR50 resp was PBO 15%; ADA 36%; FEN 50mg 18%, 150 qd 28%, 200 mg bid 35%. FEM NO effx on myeloid & B cell biomarkers.

Dr. John Cush RheumNow ( View Tweet)

May 28, 2020
NEJM reports no difference between 5d and 10d course of Remdesivir in severe Covid-19 not requiring mechanical ventilation; but this trial did not include a placebo control https://t.co/mxAR2qQzPa

Dr. John Cush RheumNow ( View Tweet)

May 28, 2020
CORRONA registry compared Triple DMARD (MSH) to TNF/MTX Rx; MSH is infrequently used; Triple DMARD pts were older, longer Dz duration, less Dz activity, more CA & comorbidities.

Dr. John Cush RheumNow ( View Tweet)

May 27, 2020

TNR Grand Rounds - Cytokine Storm Syndromes

May 27, 2020

This week's Tuesday Nite Rheumatology featured Dr Randy Cron from the University of Alabama - Birmingham as he spoke and took questions on the immunology, immunopathogenesis and treatment of Cytokine Storm Syndrome, especially as they relate to COVID-19 and rheumatic disease patients. The

Read Article
Case-control study of risk factors for [rheumatic use] hydroxychloroquine retinopathy: cumulative dose, duration of intake, creatinine clearance and geographical origin sign^ in multivariate analysis, what is driving the geo finding? genetics?

Dr Philip Robinson philipcrobinson ( View Tweet)

May 27, 2020

Hydroxychloroquine Improves Survival in Lupus

May 26, 2020

Hydroxychloroquine (HCQ) has dominated the news in recent weeks, because of poor outcomes reported when used in COVID patients. Yet, a recent report reaffirms what rheumatologists have known for years - that HCQ use is associated with better outcomes in systemic lupus erythematosus, including

Read Article

Low Risk of COVID-19 Pneumonia in Rheumatic Patients

May 25, 2020

A current letter in the Annals of Rheumatic Disease details the rheumatic disease patient cohort outcomes from the University of Siena, Italy showing only 2 cases of COVID-19 among 859 patients treated with tsDMARDs and bDMARDs.

Read Article

Again, Antimalarial Use Fails to Benefit COVID

May 22, 2020

Today Lancet reported the results of another retrospective trial showing that hydroxychloroquine or chloroquine, alone or with a macrolide antibioitic, offered no additional benefits to COVID-19 patients, but was associated with higher rates of mortality and arrhythmia.



Analysis of a

Read Article

RheumNow Podcast - Preaching to the Choir (5.22.20)

May 22, 2020

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
Metformin reduces RA risk in Women - Population study of 2.3 million, found 113749 starting metformin (1998-2014); 558 developed new RA. Adherence (PDC 40–59%) predicted lower adjusted hazard ratio = 0.62, moreso in women on 2550+ qd https://t.co/z6AWWlBpa2

Dr. John Cush RheumNow ( View Tweet)

May 22, 2020

No Certain Link between Biologics and Melanoma Risk

May 21, 2020

A review of available data fails to show an increased risk of melanoma in IMID (inflammatory bowel disease, rheumatoid arthritis, and psoriasis) patients treated with systemic biologic therapies.  



There have been sporadic uncontrolled observational reports suggesting a link between

Read Article
A patient service Video - How to Manage your Arthritis Medications (in the time of COVID) - View the video here: https://t.co/hWW0h8wCZn or listen to the podcast on iTunes or here>> https://t.co/8wV4V2pYY5
Dr. John Cush RheumNow ( View Tweet)
May 21, 2020
JAK inhibr safety review - Meta-analysis shows a significant 57% increase in risk of H. zoster with JAKi (RR 1.57; 1.04-2.37). Data from 82 studies, 66,159 pts w/ RA, IBD, Pso, PsA, AS. Rates of SIE=2.81/100PY and HZ=2.67/100 PY.

Dr. John Cush RheumNow ( View Tweet)

May 21, 2020

Anti-TNF and CNS Events: The Link Strengthens

May 20, 2020

Patients with autoimmune diseases who were treated with tumor necrosis factor (TNF) inhibitors had an increased risk of developing inflammatory central nervous system (CNS) adverse events, a nested case-control study found.

Read Article

TNR - COVID-Rheumatology Registry & COVID in OZ

May 19, 2020

This week's Tuesday Nite Rheumatology features presentations and interviews with Drs. Peter Nash and Philip Robinson. Dr. Robinson presents latest data on the Rheum-Covid.org Registry, that he helped establish under the Global Rheumatology Alliance. Dr. Nash presents the impact of COVID in

Read Article
Secukinumab shown to work in 9/15 (67%) of refractory Behçet’s patients (mucosal and articular dz) by 3 mos - Retrospective study looked a complete or partial responders. #s increased to 86.7% at 6 months.

Dr. John Cush RheumNow ( View Tweet)

May 18, 2020

High Dose Anakinra Effective in COVID-19

May 18, 2020

Anakinra was studied in 29 COVID(+) patients with respiratory distress and high inflammatory markers (CRP or ferritin) and compared to non-anakinra patients, those on anakinra had better survival (90% vs. 56% ;p=0·009) and greater improvements in CRP and pulmonary function (72% vs 50%) compared

Read Article

The Nine Lives of Hydroxychloroquine (Updated)

May 18, 2020

Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory

Read Article

RheumNow Podcast - COVID Kids and Men (5.15.20)

May 15, 2020

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
FDA has approved OTC availability of Voltaren Gel - now called Voltaren Arthritis Pain: a topical NSAID, 1st approved by FDA in 2007.

Dr. John Cush RheumNow ( View Tweet)

May 15, 2020
×